Literature DB >> 2579756

Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity.

C B Colaço, D K Male.   

Abstract

In a study of connective tissue and infectious disease sera, we have demonstrated IgM and IgG anti-cardiolipin activity, in a solid phase radioimmunoassay, in systemic lupus erythematosus (SLE), rheumatoid arthritis, syphilis and in acute malaria caused by four different species of Plasmodium. The highest values were noted in SLE (IgM anti-cardiolipin P less than 0.005, IgG anti-cardiolipin P less than 0.01), but there was no correlation with anti-dsDNA, rheumatoid factor or VDRL titres in any disease group. Anti-cardiolipin binding was significantly associated with the lupus anticoagulant, thrombocytopenia, spontaneous abortions and thromboses in the SLE patients. Ten SLE sera from this thrombotic subset and 10 syphilitic sera with similar anti-cardiolipin activity, were tested against four phospholipid antigens and showed significantly different anti-phosphatidyl ethanolamine/anti-phosphatidyl serine binding ratios (P less than 0.001). These differences in phospholipid epitope specificity could explain the specificity of the VDRL antigen in syphilis serology, and we discuss a putative role for anti-phosphatidyl serine in the thrombotic diathesis of SLE.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579756      PMCID: PMC1577146     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  [Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases].

Authors:  J R HASERICK; R LONG
Journal:  Ann Intern Med       Date:  1952-09       Impact factor: 25.391

2.  A DNA antigen that reacts with antisera to cardiolipin.

Authors:  M Guarnieri; D Eisner
Journal:  Biochem Biophys Res Commun       Date:  1974-05-20       Impact factor: 3.575

3.  Character of anti-DNA antibodies in systemic lupus erythematosus.

Authors:  S A Cohen; G R Hughes; G L Noel; C L Christian
Journal:  Clin Exp Immunol       Date:  1971-04       Impact factor: 4.330

4.  Studies of syphilitic antibodies. II. Substances responsible for biological false positive sero-reactions.

Authors:  K Aho
Journal:  Br J Vener Dis       Date:  1968-03

5.  A simple radioimmunoassay to determine binding of antibodies to lipid antigens.

Authors:  M Smolarsky
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

6.  Intrauterine death and circulating anticoagulant ("antithromboplastin").

Authors:  I M Nilsson; B Astedt; U Hedner; D Berezin
Journal:  Acta Med Scand       Date:  1975-03

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas.

Authors:  Y Shoenfeld; J Rauch; H Massicotte; S K Datta; J André-Schwartz; B D Stollar; R S Schwartz
Journal:  N Engl J Med       Date:  1983-02-24       Impact factor: 91.245

9.  Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.

Authors:  P Thiagarajan; S S Shapiro; L De Marco
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

10.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

View more
  37 in total

1.  Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection.

Authors:  B S Tzang; T Y Chen; T C Hsu; Y C Liu; G J Tsay
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.

Authors:  R Cervera; J Font; A López-Soto; F Casals; L Pallarés; A Bové; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

Review 3.  Pregnancy and antibodies to phospholipids.

Authors:  M J Walport
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

4.  Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate.

Authors:  B M Alving; B Banerji; W E Fogler; C R Alving
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

5.  Antiphospholipid antibodies and Mycoplasma pneumoniae infection.

Authors:  N Snowden; P B Wilson; M Longson; R S Pumphrey
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

Review 6.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

7.  Anti-Klebsiella K30 phospholipid antibodies in systemic lupus erythematosus: antigen cross-reactions and idiotypic sharing with antibodies to DNA and Klebsiella K30 polysaccharide.

Authors:  G D Harkiss; F M Hendrie; D Thompson
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

8.  Risk factors for thrombosis in lupus patients.

Authors:  P Hasselaar; R H Derksen; L Blokzijl; M Hessing; H K Nieuwenhuis; B N Bouma; P G De Groot
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

9.  Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis.

Authors:  S Loizou; C G Mackworth-Young; C Cofiner; M J Walport
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

10.  The H3 anti-phospholipid idiotype is found in patients with systemic lupus erythematosus (SLE) but not in patients with syphilis.

Authors:  A Hohmann; R Comacchio; V Boswarva; M Sutjita; J Bradley
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.